



TFW

TRANSMITTAL FORM <i>(To be used for all correspondence after initial filing)</i>	Application Number	10/801.122
	Filing Date	March 15, 2004
	First Named Inventor	Edward A. Neuwelt
	Art Unit	1614
	Examiner Name	
	Attorney Docket No.	720109.405


ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> CD(s), Number of CD(s) _____
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Request for Corrected Filing Receipt	<input type="checkbox"/> After Allowance Communication to Technology Center (TC)
<input type="checkbox"/> Amendment/Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (<i>Appeal Notice, Brief, Reply Brief</i>)
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Declaration	<input checked="" type="checkbox"/> Return Receipt Postcard
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement	<input type="checkbox"/> Statement under 37 CFR 3.73(b)	<input type="checkbox"/> Additional Enclosure(s) (please identify below): _____ _____ _____
<input checked="" type="checkbox"/> Form PTO-1449	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Cited References (X 6)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53		
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Individual Name	Qing Lin, Ph.D.	Customer Number 00500
Signature		
Date	October 18, 2004	

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or printed name	Jennifer J. Fortuny	
Signature		Date: October 18, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
523837_1.DOC




PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

October 18, 2004

Date


Jennifer J. Fortuny

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Edward A. Neuwelt
Application No. : 10/801,122
Filed : March 15, 2004
For : USE OF THIOL-BASED COMPOSITIONS IN AMELIORATING
MUSCOSAL INJURY

Art Unit : 1614
Docket No. : 720109.405
Date : October 18, 2004

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicant wishes to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449. Applicant notes that since the application filing date is after June 30, 2003, copies of the cited U.S. patents and published patent applications are not required and accordingly have not been provided. Copies of all other cited references are enclosed. As to any reference cited, applicant does not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserves the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicant's duty to disclose all information he/she is aware


of which is believed relevant to the examination of the above-identified application, applicant believes that his/her invention is patentable.

I hereby certify that each of the references set forth on the attached form PTO-1449 was first cited in a communication from a foreign patent office in a counterpart foreign application and that this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicant believes this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC




Qing Lin, Ph.D.
Registration No. 53,937

Enclosures:

Postcard
Form PTO-1449
Cited References (X 6)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	ATTY. DOCKET NO. 720109.405	APPLICATION NO. 10/801,122
			APPLICANT Edward A. Neuwelt	
			FILING DATE March 15, 2004	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,994,409	11/30/99	Stongniew et al.	514	665	
	AB						
	AC						
	AD						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AE	02/17962 A2	03/07/02	WO		
	AF	02/41837 A2	05/30/02	WO		
	AG					
	AH					
	AI					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AJ	Neuwelt, E. A. et al., "Therapeutic Efficacy of Aortic Administration of N-Acetylcysteine as a Chemoprotectant against Bone Marrow Toxicity after Intracarotid Administration of Alkylators, with or without Glutathione Depletion in a Rat Model," <i>Cancer Research</i> , 61:7868-7874, November 1, 2001, XP-002978234.
	AK	Martinez, et al., "N-acetylcysteine as chemoprotectant in cancer chemotherapy," <i>The Lancet</i> , 338(8761):249-250, July 27, 1991, XP-002083106
	AL	Sridharan, S. and Shyamaladevi, C.S., "Protective Effect of N-acetylcysteine Against Gamma Ray Induced Damages in Rats – Biochemical Evaluations," <i>Indian Journal of Experimental Biology</i> , 40(2):181-186, February 2002, XP009036211.
	AM	Uozumi, J. et al., "Effectiveness of "Two-route Chemotherapy" Using Cisplatin and Its Antidote, Sodium Thiosulfate, on Lifespan of Rats Bearing Metastatic Liver Tumors," <i>Cancer Treatment Reports</i> , 67(12):1067-1074, December 1983, XP008010094.
	AN	
	AO	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).